Search PubMed⌕ Search
Home/Archive/PubMed

PubMed · 6430767

Nitrate tolerance.

J O Parker
View original source ↗Export metadata ↓

Abstract

These studies have shown the following: Tolerance to the hemodynamic and antianginal effects of isosorbide dinitrate. Tolerance develops quickly and can be demonstrated within 24 hours. Tolerance is rapidly reversed and the return of normal responsiveness is seen within 21 hours withdrawal of isosorbide dinitrate. Cross-tolerance occurs between the hemodynamic effects of isosorbide dinitrate and nitroglycerin. When tolerance is present, the next dose of isosorbide dinitrate does exert an effect, although somewhat less in magnitude and duration. Sublingual isosorbide dinitrate and nitroglycerin restores exercise performance despite tolerance to oral isosorbide dinitrate.

Explore related subjects

Angina PectorisClinical Trials as TopicDose-Response Relationship, DrugDouble-Blind MethodDrug ToleranceExercise TestHemodynamicsHumansIsosorbide DinitrateLong-Term CareMaleNitroglycerinClinical TrialJournal Article

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

J O Parker. 1984. Nitrate tolerance.. https://pubmed.ncbi.nlm.nih.gov/6430767/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

PubMed1992

Comparison of painful and painless left ventricular dysfunction recorded during ambulatory ventricular function monitoring in angina pectoris secondary to coronary artery disease.

Left ventricular (LV) function and the electrocardiogram of 55 patients with coronary artery disease and angina were monitored for a mean of 3.2 +/- 1.9 hours with an ambulatory LV function monitor. During the monitoring interval, patients performed daily activities such as sitting, walking, climbing stairs, and eating. Sixty episodes of transient reduction in ejection fraction of > 5% lasting > 60 seconds were observed in 24 patients; 13 episodes were associated with typical angina, but 47 were asymptomatic. Asymptomatic episodes had a shorter duration of ventricular dysfunction (116 +/- 49 vs 189 +/- 113 seconds; p < 0.05), and smaller increases in relative end-diastolic and end-systolic volumes (end-diastolic 0.9 +/- 5.4% vs 4.6 +/- 4.9% [p < 0.05], and end-systolic 21 +/- 11% vs 35 +/- 20% [p < 0.05]) than did symptomatic ones. When a subset of patients with both symptomatic and asymptomatic episodes were analyzed, similar results were observed: in asymptomatic episodes, duration was shorter (82 +/- 31 vs 200 +/- 110 seconds; p < 0.005), ejection fraction decrease was smaller (-7.3 +/- 2.6% vs -11.0 +/- 4.7%; p < 0.05), and end-systolic volume increase was smaller (23 +/- 12% vs 37 +/- 19%; p < 0.05). The data suggest that asymptomatic transient LV dysfunction is less severe and of shorter duration in patients with angina pectoris.

Angina Pectoris↗
PubMed1992

[Angina pectoris after sumatriptan (Imigran)].

Developed for the treatment of migraine, sumatriptan is an agonist of 5-hydroxytryptamine-1-receptors. Though a pressure sensation is a common complaint, significant ECG changes have not been reported after subcutaneous administration of sumatriptan. A case history is given where angina pectoris after sumatriptan self-administration was experienced on two occasions by a 61-year old man with a history of minor myocardial infarction--without post-infarction angina--two years previously. The angina after sumatriptan was accompanied on both occasions by significant ST-segment depression on ECG-monitoring. An extracranial vasoconstrictor action of sumatriptan in patients with ischaemic heart disease is suggested.

Angina Pectoris↗